Pediatric-type follicular lymphoma in a Crohn’s disease patient receiving anti-α4β7-integrin therapy: A case report

Table 1 Peripheral blood lymphocyte subsets, and B- and T-lymphocyte clonality

Component	Ref range & units	Testing time point
		Pre-Tx	EOTx	12 mo off Tx
CD3+ T cell	60%-89%	43	72	52
CD3+ T cell	958-2388 cells/uL	473	792	869
CD3+CD4+ T cell	34%-61%	27	39	32
CD3+CD4+ T cell	533-1674 cells/uL	304	425	526
CD3+CD8+ T cell	10%-41%	14	28	18
CD3+CD8+ T cell	175-958 cells/uL	151	303	293
CD19+ B cell	5%-22%	20	0	23
CD19+ B cell	75-660 cells/uL	224	0	385
NK cell	5%-25%	37	27	24
NK cell	102-565 cells/uL	406	297	394
CD4/CD8 ratio	1.10-3.25	2.02	1.40	1.79
B cell clonality
IGH FR1		Nonclonal		Nonclonal
IGH FR2		Nonclonal		Nonclonal
IGH FR3		Nonclonal		Nonclonal
IGH DH1-6-J		Nonclonal		Nonclonal
IGK V-J		Nonclonal		Nonclonal
IGK V-Kde		Nonclonal		Nonclonal
TCR clonality
TCRB A (V-J)		Nonclonal		Nonclonal
TCRB B (V-J)		Nonclonal		Nonclonal
TCRB C (V-J)		Clonal peak (180 bp)		Clonal peak (180 bp)
TCRG D		Clonal peak (189 bp)		Nonclonal

pre-Tx: Pre-treatment; EOTx: End of therapy; 12 mo off Tx: 12 mo off therapy anti-lymphoma therapy; NK: Natural killer; TCR: T cell receptor.